drugset / Trial / NCT04264819
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
NaSingle-groupOpen-labelTreatment
Summary
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid exudation, and fibrosis, resulting in photoreceptor damage and vision loss.
Timeline
- Start
- 2020-12-14
- Primary completion
- 2022-10-05
- Completion
- 2023-05-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brolucizumab | Other / unclassified | 6 mg | — |